Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecast
Data as of Aug 2, 2026Healthcare · Current price $26.86 (-3.88%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Doug Tsao | H.C. Wainwright | $34.00 | +26.6% |
| Nov 28, 2025 | Uy Ear | Mizuho Securities | $37.00 | +37.7% |
| Oct 30, 2025 | Richard Law | Goldman Sachs | $29.00 | +7.9% |
| Oct 29, 2025 | Douglas Tsao | H.C. Wainwright | $30.00 | +11.7% |
| Oct 29, 2025 | Uy Ear | Mizuho Securities | $32.00 | +19.1% |
| Dec 30, 2024 | Douglas Tsao | H.C. Wainwright | $19.00 | -29.3% |
| May 15, 2024 | Serge Belanger | Needham | $18.00 | -33.0% |
| May 15, 2024 | Uy Ear | Mizuho Securities | $18.00 | -33.0% |
| Apr 27, 2022 | Eric Cha | Goldman Sachs | $37.00 | +37.7% |
Top Analysts Covering ARQT
ARQT vs Sector & Market
| Metric | ARQT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +26.6% | +16316.1% | +17.1% |
| P/E Ratio | -185.06 | 3.18 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $127M | $129M | $132M | 1 |
| 2026-12-31 | $144M | $147M | $150M | 2 |
| 2027-03-31 | $135M | $138M | $140M | 1 |
| 2027-06-30 | $151M | $154M | $157M | 2 |
| 2027-09-30 | $165M | $168M | $171M | 2 |
| 2027-12-31 | $179M | $182M | $185M | 1 |
| 2028-12-31 | $785M | $785M | $785M | 8 |
| 2029-12-31 | $898M | $920M | $957M | 7 |
| 2030-12-31 | $1.03B | $1.06B | $1.10B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.12 | $0.12 | $0.12 | 1 |
| 2026-12-31 | $0.20 | $0.21 | $0.21 | 2 |
| 2027-03-31 | $0.06 | $0.06 | $0.06 | 2 |
| 2027-06-30 | $0.14 | $0.14 | $0.14 | 1 |
| 2027-09-30 | $0.20 | $0.21 | $0.21 | 1 |
| 2027-12-31 | $0.27 | $0.28 | $0.29 | 2 |
| 2028-12-31 | $1.39 | $1.97 | $2.76 | 6 |
| 2029-12-31 | $2.54 | $2.63 | $2.76 | 4 |
| 2030-12-31 | $2.95 | $3.04 | $3.20 | 2 |
Frequently Asked Questions
What is the analyst consensus for ARQT?
The consensus among 6 analysts covering Arcutis Biotherapeutics, Inc. (ARQT) is Buy with an average price target of $34.00.
What is the highest price target for ARQT?
The highest price target for ARQT is $37.00, set by Uy Ear at Mizuho Securities on 2025-11-28.
What is the lowest price target for ARQT?
The lowest price target for ARQT is $18.00, set by Uy Ear at Mizuho Securities on 2024-05-15.
How many analysts cover ARQT?
6 analysts have issued ratings for Arcutis Biotherapeutics, Inc. in the past 12 months.
Is ARQT a buy or sell right now?
Based on 6 analyst ratings, ARQT has a consensus rating of Buy (2.00/5) with a +26.6% upside to the consensus target of $34.00.
What are the earnings estimates for ARQT?
Analysts estimate ARQT will report EPS of $0.12 for the period ending 2026-09-30, with revenue estimated at $129M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.